Veru Inc. (VERU)’s President and CEO Mitchell Steiner Acquires 20000 shares of the Company; FANLOGIC INTERACTIVE ORDINARY SHARES (FNNGF) Shorts Raised By 252.38%

FANLOGIC INTERACTIVE INC ORDINARY SHARES (OTCMKTS:FNNGF) had an increase of 252.38% in short interest. FNNGF’s SI was 22,200 shares in March as released by FINRA. Its up 252.38% from 6,300 shares previously. With 96,400 avg volume, 0 days are for FANLOGIC INTERACTIVE INC ORDINARY SHARES (OTCMKTS:FNNGF)’s short sellers to cover FNNGF’s short positions. The SI to FANLOGIC INTERACTIVE INC ORDINARY SHARES’s float is 0.06%. The stock decreased 6.29% or $0.0096 during the last trading session, reaching $0.1431. About shares traded. Fanlogic Interactive Inc. (OTCMKTS:FNNGF) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.

Mitchell Steiner, President and CEO of Veru Inc, in an insider transaction invested in 20,000 shares whose sum is estimated to be $29,996 at average stock price of $1.5. Mitchell Steiner presently has 7.79 million shares or 14.57% of Veru Inc’s market cap. The filing was revealed in a filing dated 06-03-2018 with the SEC.

Fanlogic Interactive Inc. operates as a digital and social engagement company. The company has market cap of $8.29 million. The firm provides brands with user data, and advanced analytics and insights; and brand management and lead generation services for users to consume content on behalf of brands. It currently has negative earnings. It operates FanLogic Connect, a proprietary SAAS product that enables companies of various sizes to create, launch, and manage their own digital social promotional campaigns.

Veru Inc., a medical therapeutics company, develops, makes, and markets consumer health care products. The company has market cap of $87.23 million. The companyÂ’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It currently has negative earnings. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus.

The stock increased 13.99% or $0.2 during the last trading session, reaching $1.63. About 258,009 shares traded or 114.99% up from the average. Veru Inc. (NASDAQ:VERU) has 0.00% since March 7, 2017 and is . It has underperformed by 16.70% the S&P500.